GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery
GV20 Therapeutics will leverage the resources provided by NVIDIA Inception to develop new AI models for drug discovery,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Mar 24
GV20 Therapeutics will leverage the resources provided by NVIDIA Inception to develop new AI models for drug discovery,…
12 Mar 24
The global collaboration and exclusive option-to-license agreement focuses on novel G protein-coupled receptor (GPCR) targets to improve patient…
11 Mar 24
The data from FRONTIER 2, the long-term extension to Phase 2b FRONTIER 1 study, showed that JNJ-2113 resulted…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Mar 24
The approval was based on Wegovy's efficacy and safety results from the SELECT cardiovascular outcomes study in which…
08 Mar 24
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was…
06 Mar 24
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…
05 Mar 24
Acoramidis is an investigational, next-generation, orally administered, highly potent and selective small molecule transthyretin (TTR) stabiliser, intended for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 24
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
01 Mar 24
Abrysvo bivalent RSV vaccine showed 77.8% efficacy against RSV-associated LRTD after disease surveillance in season two, and 88.9%…
29 Feb 24
Ginkgo Bioworks has acquired synthetic biology company Patch Biosciences, pharmaceutical company Reverie Labs, and CRISPR-based diagnostic test developer…